NCT06951880View on ClinicalTrials.gov

A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

June 27, 2025

Primary Completion Date

September 24, 2026

Study Completion Date

September 24, 2026

Conditions
Healthy Participants
Interventions
DRUG

AZD4916

AZD4916 will be administered as oral solution.

OTHER

Placebo

Placebo will be administered as oral solution.

Trial Locations (1)

HA1 3UJ

Research Site, Harrow

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT06951880 - A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers | Biotech Hunter | Biotech Hunter